Your browser doesn't support javascript.
Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses.
Needham, Edward J; Ren, Alexander L; Digby, Richard J; Norton, Emma J; Ebrahimi, Soraya; Outtrim, Joanne G; Chatfield, Doris A; Manktelow, Anne E; Leibowitz, Maya M; Newcombe, Virginia F J; Doffinger, Rainer; Barcenas-Morales, Gabriela; Fonseca, Claudia; Taussig, Michael J; Burnstein, Rowan M; Samanta, Romit J; Dunai, Cordelia; Sithole, Nyarie; Ashton, Nicholas J; Zetterberg, Henrik; Gisslén, Magnus; Edén, Arden; Marklund, Emelie; Openshaw, Peter J M; Dunning, Jake; Griffiths, Michael J; Cavanagh, Jonathan; Breen, Gerome; Irani, Sarosh R; Elmer, Anne; Kingston, Nathalie; Summers, Charlotte; Bradley, John R; Taams, Leonie S; Michael, Benedict D; Bullmore, Edward T; Smith, Kenneth G C; Lyons, Paul A; Coles, Alasdair J; Menon, David K.
  • Needham EJ; Department of Clinical Neurosciences, University of Cambridge, UK.
  • Ren AL; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.
  • Digby RJ; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.
  • Norton EJ; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.
  • Ebrahimi S; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.
  • Outtrim JG; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.
  • Chatfield DA; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.
  • Manktelow AE; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.
  • Leibowitz MM; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.
  • Newcombe VFJ; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.
  • Doffinger R; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.
  • Barcenas-Morales G; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.
  • Fonseca C; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.
  • Taussig MJ; Cambridge Protein Arrays Ltd, Babraham Research Campus, Cambridge, UK.
  • Burnstein RM; Cambridge Protein Arrays Ltd, Babraham Research Campus, Cambridge, UK.
  • Samanta RJ; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.
  • Dunai C; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.
  • Sithole N; Clinical Infection Microbiology and Neuroimmunology, Institute of Infection, Veterinary and Ecological Science, Liverpool, UK.
  • Ashton NJ; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
  • Zetterberg H; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Gisslén M; Jeffrey Cheah Biomedical Centre, Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
  • Edén A; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Marklund E; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Openshaw PJM; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Dunning J; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
  • Griffiths MJ; UK Dementia Research Institute at UCL, London, UK.
  • Cavanagh J; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.
  • Breen G; Department of Infectious Diseases, Institute of Biomedicine, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Irani SR; Department of Infectious Diseases, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Elmer A; Department of Infectious Diseases, Institute of Biomedicine, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Kingston N; Department of Infectious Diseases, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Summers C; Department of Infectious Diseases, Institute of Biomedicine, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Bradley JR; Department of Infectious Diseases, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Taams LS; National Heart and Lung Institute, Imperial College London, London, UK.
  • Michael BD; Nuffield Department of Medicine, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
  • Bullmore ET; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
  • Smith KGC; Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  • Lyons PA; Department of Social Genetic and Developmental Psychiatry, King's College London, London, UK.
  • Coles AJ; Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Menon DK; Department of Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Brain ; 145(11): 4097-4107, 2022 11 21.
Article in English | MEDLINE | ID: covidwho-2017743
ABSTRACT
COVID-19 is associated with neurological complications including stroke, delirium and encephalitis. Furthermore, a post-viral syndrome dominated by neuropsychiatric symptoms is common, and is seemingly unrelated to COVID-19 severity. The true frequency and underlying mechanisms of neurological injury are unknown, but exaggerated host inflammatory responses appear to be a key driver of COVID-19 severity. We investigated the dynamics of, and relationship between, serum markers of brain injury [neurofilament light (NfL), glial fibrillary acidic protein (GFAP) and total tau] and markers of dysregulated host response (autoantibody production and cytokine profiles) in 175 patients admitted with COVID-19 and 45 patients with influenza. During hospitalization, sera from patients with COVID-19 demonstrated elevations of NfL and GFAP in a severity-dependent manner, with evidence of ongoing active brain injury at follow-up 4 months later. These biomarkers were associated with elevations of pro-inflammatory cytokines and the presence of autoantibodies to a large number of different antigens. Autoantibodies were commonly seen against lung surfactant proteins but also brain proteins such as myelin associated glycoprotein. Commensurate findings were seen in the influenza cohort. A distinct process characterized by elevation of serum total tau was seen in patients at follow-up, which appeared to be independent of initial disease severity and was not associated with dysregulated immune responses unlike NfL and GFAP. These results demonstrate that brain injury is a common consequence of both COVID-19 and influenza, and is therefore likely to be a feature of severe viral infection more broadly. The brain injury occurs in the context of dysregulation of both innate and adaptive immune responses, with no single pathogenic mechanism clearly responsible.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Brain Injuries / Influenza, Human / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Brain Year: 2022 Document Type: Article Affiliation country: Brain

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Brain Injuries / Influenza, Human / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Brain Year: 2022 Document Type: Article Affiliation country: Brain